Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health, today announced that it has completed its merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research.
Related news for (LAB)
- Today’s Top Performers: MoBot’s Market Review 08/22/25 09:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/22/25 08:00 AM
- Today’s Top Performers: MoBot’s Market Review 06/23/25 09:00 AM
- Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
- 24/7 Market News Snapshot 23 June, 2025 – Standard BioTools Inc. Common Stock (NASDAQ:LAB)